Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

K-Fast Holding AB (publ): Interim report January-September 2023

*New issue has raised SEK 331 million to the company.*SEK 554 million in profit settlement in ongoing construction, shown as unrealized values, since Q2 2022 when property values peaked which meets decreased values due to falling valuations of completed properties.*Positive net letting since internal rental organization for all succession letting as well as project letting was established in mid May. Financial ratios for the period 1 January–30 September 2023(corresponding period in 2022 unless other stated) · Rental income: SEK 351.5 million (275.1) · Profit from property

Wärtsilä and Seaspan transform maritime operations with SmartDock autodocking system

Wärtsilä Corporation, Trade press release, 9 November 2023 at 10:00 AM EETWärtsilä ANCS, part of technology group Wärtsilä, has delivered to Seaspan, a marine transportation and shipbuilding company, the cutting-edge autonomous SmartDock capabilities to the seas. This delivery marks a significant step towards autonomous docking and undocking operations, making maritime activities safer and more efficient. The SmartDock system developed by Wärtsilä ANCS enables Seaspan to perform autonomous docking manoeuvres even in challenging conditions, where currents reach up to two knots. With its

Invitation to Sensys Gatso’s presentation of the Interim Report for Q3 2023

Sensys Gatso Group, a global leader in traffic safety solutions, publishes the financial report for the third quarter 2023 at 8.30 am CET on Thursday November 16 and hereby invites to a presentation/audiocast at 10 am CET. The company’s CEO Ivo Mönnink and CFO Simon Mulder will present the financial results in English.The presentation/audiocast can be joined online or via telephone and will be available on the company’s webpage https://www.sensysgatso.com If you wish to participate via webcast please use the link below.https://ir.financialhearings.com/sensys-gatso-group-q3-2023 If

Sciety’s portfolio company Neogap raises SEK 83 million

Sciety och Sciety Venture Partners have invested SEK 54 million in Neogap Therapeutics (Neogap), a Swedish clinical-stage biotech company that develops personalised immunotherapy for cancer treatment with the help of two emerging technologies. The company has also been awarded roughly SEK 29 million in innovation funding from the EU. The capital will be used to complete the company’s ongoing phase I/IIa clinical study with patients with colorectal cancer.Neogap’s immunotherapy uses the patient’s own immune cells to create a tailored treatment that is adapted to the patient and their

Interim report, July - September 2023

In Q3 2023 net sales increased by 33% compared to Q3 2022. Consolidated net sales ended at 81,188 (SEK 000s). EBITDA totaled to -6,882 (SEK 000s). Operating profit, EBIT, was -30,249 (SEK 000s). Profit after tax was -23,725 (SEK 000s). Earnings per share was SEK -0.35.CEO's comments Continued strong performance with increased growth; on-track with the profitable growth strategy 24SevenOffice Group AB continues to execute on the profitable growth-oriented strategy. This quarter's results are a clear reflection of the outcomes anticipated from our strategic growth investment strategy,

Salmon Evolution ASA: Invitation to presentation of results for the third quarter 2023

Salmon Evolution will present the third quarter 2023 results followed by a Q&A session, on Wednesday 15 November 2023 08:00 CET, at Hotel Continental in Oslo. A light snack will be served from 07:45 CET. Participants may also follow the presentation and submit questions through a live webcast available on www.salmonevolution.no, or with the following link: https://events.webcast.no/salmon-evolution/OEpmPDaoyhi5siPjdg0b/YpjX2kRpv5cFisuvNmU6 The presentation and Q&A will be held in English by CEO Trond Håkon Schaug-Pettersen and CFO Trond Vadset Veibust. Please note that the

Interim Report Q3 – January – September, 2023 Redsense Medical AB (publ)

JULY – SEPTEMBER 2023 · Net sales amounted to kSEK 5,287 (1,023), an increase of 417%. · Operating loss, EBIT amounted to kSEK 959 (5,857).  · Result after tax amounted to kSEK -1,008 (-2,372).  · Earnings per share were SEK -0.07 (-0.17). SIGNIFICANT EVENTS DURING THE PERIOD · On July 7, Redsense alarm system was featured in KFF Health News · On August 15, Redsense secured a strong autumn with a mSEK 11.2 order. · On September 27, Redsense Medical arranged Congressional Briefing to address Venous Needle Dislodgement. · On September 28, Redsense announced that

BioStock: Altium fuels PHI’s forward drive

PHI’s largest investor, Altium S.A., has intensified its support for the company with a directed share issue of 9.9 MSEK, subject to approval at an extraordinary shareholder meeting on November 15. This investment extends PHI’s financial runway beyond 2025 and accelerates its GMP and regenerative medicine projects. BioStock connects with Goran Dubravčić, who serves as Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore these pivotal developments and their impact on PHI’s trajectory.Read the full interview with Goran Dubravčić at biostock.se: https://www.biostock.se/

Himalaya Shipping Ltd. (HSHP) – Commercial Update

Hamilton, Bermuda, November 9, 2023 In October 2023, the Company achieved average time charter equivalent (“TCE”) earnings of approximately US$35,400 per day, gross[1]. The Company’s five vessels trading on index-linked time charters earned approximately US$36,500 per day, gross, including average daily scrubber and LNG benefits of approximately US$1,300 per day. The Company’s only vessel trading on a fixed time charter earned US$30,000 per day, gross. The Baltic 5TC Capesize Index averaged US$25,557 during October 2023. For further queries, please contact:   Herman Billung,

Low-IT resource finance projects made possible with Aico to SAP middleware integration solution.

Since cost and scarcity of IT resources are holding back finance process development projects, Aico has created an industry-leading SAP integration implementation process, saving enterprise companies time and IT resources, whilst ensuring the security of company data.Finnish financial and accounting automation software company Aico Group Oy has accelerated its integration implementation for enterprise companies that use SAP middleware.  Aico software platform manages and automates the entire record-to-report process for financial professionals, providing best-in-class live integration to

Low-IT resource finance projects made possible with Aico to SAP middleware integration solution.

Since cost and scarcity of IT resources are holding back finance process development projects, Aico has created an industry-leading SAP integration implementation process, saving enterprise companies time and IT resources, whilst ensuring the security of company data.Finnish financial and accounting automation software company Aico Group Oy has accelerated its integration implementation for enterprise companies that use SAP middleware.  Aico software platform manages and automates the entire record-to-report process for financial professionals, providing best-in-class live integration to

Immunovia Publishes Interim Report for January-September 2023

July-September 2023 · Net sales amounted to KSEK 488 (358) divided by sales of tests KSEK 70 (111) and royalties KSEK 418 (247). · Net earnings were MSEK -38.6 (-22.9) and earnings per share before and after dilution were SEK -0.91 (1.01). · Cash Flow from operating activities amount to MSEK -35 (-37). · Cash and equivalents at the end of the period amounted to MSEK 107 (159). · On July 11, the Company announced that it will cease commercialization of IMMray™ PanCan-d test in the United States to focus its resources on development of the next-generation pancreatic cancer

ORGANOCLICK AB (PUBL) PUBLISH INTERIM REPORT FOR Q3 2023

"The third quarter showed good sales with 50 percent growth. Both the Nonwoven & fiber technologies and the Green coatings & maintenance products business unit saw robust growth. On the other hand, the Functional wood business unit continued to face harsh market conditions and saw a decrease in sales. Our operating profit/loss improved to MSEK -2.8 (-7.9) thanks to the increasing sales."Translation from CEO Mårten Hellbergs comments to the Interim Report. Q3, 1 July - 30 September 2023 The Group compared with 2022 » Net revenue amounted to SEK 33.45 (22.26) million » The gross

Pihlajalinna Plc: Managers’ transactions

Pihlajalinna Plc      Managers’ transactions     9 November 2023 at 9:30 a.m. Pihlajalinna Plc: Managers’ transactions Pihlajalinna Plc has received the following notification on 8 November 2023: Person subject to the notification requirementName: Tuomas HyyryläinenPosition: Chief Executive OfficerIssuer: Pihlajalinna OyjLEI: 74370058MTRLEDOCHV67Notification type: INITIAL NOTIFICATIONReference number: 42956/5/10____________________________________________Transaction date: 2023-11-07Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000092556

Information about the Annual Report 2022/23

Diamyd Medical today publishes the Annual Report for 2022/23 in Swedish and announces the following change in the Annual Report compared to the Year-end Report, which was published on October 11, 2023.Diamyd Medical's partnership with JDRF[*] means that JDRF contributes with financial   support. Payments from JDRF are earned when Diamyd Medical completes various milestones in the DIAGNODE-3 study, with these milestones spanning the years 2023 - 2027. JDRF can also use its global type 1 diabetes network to raise awareness of the study, which may contribute to patient recruitment, and also

TORM purchases eight LR2 vessels

On 09 November 2023, TORM has entered into an agreement to acquire eight second-hand LR2 vessels that are expected to be delivered in late Q4 2023 and in Q1 2024 for a total consideration of USD 399m, with a cash consideration of USD 239m and the issuance of approximately 5.5 million shares (1). The purchase price is subject to certain adjustments that will be impacted by TORM’s share price development and the vessels’ delivery schedules.   The vessels have all been built at the Tier 1-Korean yard Hyundai Samho Heavy Industries in 2010-2012 and have fuel-efficient eco vessel

Rejlers at top 5 when Sweden's Best Employer is appointed by employees

When the results of Sweden's Best Employer 2023 were released today, Rejlers placed fifth in the Large Employers category. A characteristic feature of the ranking, which is conducted annually by the Employer Branding company Universum, is that the company's own employees rate their employer. In this year's ranking, Rejlers also retains first place as the technology consulting industry's best employer, for the third year in a row.When Rejlers' employees are asked what makes the company an attractive place to work, there are several things that are highly valued: great variety in assignments

Imfinzi combination improves PFS in liver cancer

09 November 2023 Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial First global Phase III trial to show improved clinical outcome for systemic therapyin combination with transarterial chemoembolisation (TACE) in this setting Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in

Non-Executive Director Appointment and Lancashire Board Chair Succession Planning

LANCASHIRE HOLDINGS LIMITED 9th November 2023 Hamilton, Bermuda Lancashire Holdings Limited (“Lancashire”/“LHL”) - Non-Executive Director Appointment and Lancashire Board Chair Succession Planning Lancashire announces the appointment of Philip Broadley as a Non-Executive Director of LHL with effect from 8 November 2023.  Mr Broadley has also been appointed as the LHL Chair designate, and Lancashire expects his appointment as Chair to take effect immediately following Lancashire’s 2024 AGM to be held on 1 May 2024 (“the 2024 AGM”), subject to shareholder approval. Peter Clarke,

Agreement with Eccogene for clinical stage GLP-1RA

09 November 2023 AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity Global rights to Eccogene's next-generation oral glucagon-like peptide 1 receptor agonist, ECC5004 as monotherapy and combination therapies AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions. Preliminary results from the Phase I trial have shown a differentiating

Anora’s financial reporting and Annual General Meeting in 2024

Anora Group Plc   Stock Exchange Release   9 November 2023 at 9:00 a.m. EET Anora’s financial reporting and Annual General Meeting in 2024 Anora will publish financial reports in 2024 as follows: 14 February 2024: Financial Statements Bulletin for 2023 7 May 2024: Interim Report for January-March 2024 20 August 2024: Half-Year Report for January-June 2024 7 November 2024: Interim Report for January-September 2024 These financial reports will be published at approximately 8:30 a.m. Finnish time. Anora applies a silent period of 30 days before the publication of financial

Lytix Biopharma presents third quarter 2023 results

Oslo, 09 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its third quarter 2023 results. Dr. Øystein Rekdal, Chief Executive Officer of Lytix Biopharma, commented: “We continue our efforts to demonstrate the clinical benefits of LTX-315 in patients with skin cancers. First and foremost, we are satisfied with the encouraging disease control rate achieved in late stage and heavily pretreated melanoma patients in the ATLAS-IT-05 study. Secondly, we recognize the large commercial potential that could be

Quickbit signs its first customer on Abicart's e-commerce platform

Today, Quickbit announces that the first customer on Abicart's e-commerce platform has been signed. This marks the initial step in Quickbit's strategic collaboration with Abicart, providing Quickbit access to a large and growing network of merchants.In early November 2023, Quickbit entered into a cooperation agreement with the e-commerce platform Abicart. This collaboration grants Quickbit access to an extensive network of merchants, totaling approximately 2500. Now, Quickbit signs its first merchant through the platform – a vendor of locks and security products. The merchant has

Interim report January – September 2023

CONTINUED STRONG PROFIT – INCREASED VOLUMESJuly – September 2023 · Sales volume amounted to 4,819 tonnes (3,817 tonnes) an increase by 26%. · Net sales amounted to SEK 262.9 million (SEK 232.0 million), an increase by 13%. The organic increase was 5%. · Operating profit amounted to SEK 28.0 million (SEK 10.8 million), an increase by 159%. · The operating margin increased to 10.7% (4.7%) · Profit for the period amounted to SEK 20.8 million (SEK 7.6 million), an increase by 174%. · Earnings per share before dilution amounted to SEK 1.03 (SEK 0.38) and after dilution to SEK

There are no items matching the current filter
There are no more items matching the current filter
Back to top